Jpmorgan Chase & CO Volitionrx LTD Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VNRX
# of Institutions
31Shares Held
8.19MCall Options Held
53.6KPut Options Held
300-
Lagoda Investment Management, L.P. New York, NY5.44MShares$3.26 Million1.93% of portfolio
-
Vanguard Group Inc Valley Forge, PA637KShares$382,0000.0% of portfolio
-
Geode Capital Management, LLC Boston, MA635KShares$380,7280.0% of portfolio
-
Black Rock Inc. New York, NY516KShares$309,6430.0% of portfolio
-
Cowen Prime Advisors LLC179KShares$107,2420.09% of portfolio
About VOLITIONRX LTD
- Ticker VNRX
- Exchange NYSE
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 57,297,000
- Market Cap $34.4M
- Description
- VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating sampl...